局限性前列腺癌治疗5年患者报告结局比较
这项前瞻性人群队列研究纳入2005例局限性前列腺癌男性,比较主动监测、前列腺切除术、近距离放疗和外照射放疗联合或不联合雄激素剥夺治疗的功能结局。多数功能差异在5年内减弱,但前列腺切除术后尿失禁持续较差,不利风险疾病术后5年性功能劣于外照射联合ADT。
要点
- 前列腺切除术后5年尿失禁较其他方案临床意义更差。
- 有利风险者近距离放疗1年泌尿刺激、性及肠道功能较差。
- 外照射放疗有利风险者5年内功能与主动监测无临床差异。
核心结论
- 多数治疗相关功能差异在5年内减弱,但前列腺切除术后尿失禁持续临床意义较差。
- 不利风险疾病前列腺切除术后5年性功能劣于外照射联合ADT。
研究设计与样本
- 前瞻性人群队列研究,纳入1386例有利风险和619例不利风险局限性前列腺癌男性,2011-2012年诊断,随访至2017年9月。
- 暴露包括主动监测363例、保留神经前列腺切除675例、外照射放疗261例、低剂量率近距离放疗87例(有利风险),及前列腺切除402例、外照射联合ADT 217例(不利风险)。
主要发现
- 有利风险者前列腺切除术后5年尿失禁校正均差-10.9(95%CI -14.2至-7.6),3年性功能-15.2(95%CI -18.8至-11.5),均差于主动监测。
- 有利风险者近距离放疗后1年泌尿刺激-7.0(95%CI -10.1至-3.9)、性功能-10.1(95%CI -14.6至-5.7)、肠道-5.0(95%CI -7.6至-2.4),均差于主动监测。
- 有利风险者外照射放疗5年内泌尿、性及肠道功能与主动监测无临床差异。
- 不利风险者外照射联合ADT在6个月激素功能-5.3(95%CI -8.2至-2.4)、1年肠道-4.1(95%CI -6.3至-1.9)较差,但5年性功能12.5(95%CI 6.2-18.7)和尿失禁23.2(95%CI 17.7-28.7)优于前列腺切除。
关键数值与推荐
- 最小临床重要差异:性功能10-12,尿失禁6-9,泌尿刺激5-7,肠道及激素功能4-6。
- 功能评分采用26项扩展前列腺指数复合量表,范围0-100。
临床怎么用
- 咨询时应告知前列腺切除术后尿失禁可能持续5年且临床意义较差。
- 有利风险者可考虑外照射放疗,5年内功能与主动监测无临床差异。
- 不利风险者选择外照射联合ADT时,5年性功能和尿失禁优于前列腺切除。
局限性
- 观察性队列设计,治疗选择非随机,可能存在残余混杂。
- 仅纳入5个SEER站点及一个注册队列,77%为非西班牙裔白人,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Understanding adverse effects of contemporary treatment approaches for men with favorable-risk and unfavorable-risk localized prostate cancer could inform treatment selection. OBJECTIVE: To compare functional outcomes associated with prostate cancer treatments over 5 years after treatment. DESIGN, SETTING, AND PARTICIPANTS: Prospective, population-based cohort study of 1386 men with favorable-risk (clinical stage cT1 to cT2bN0M0, prostate-specific antigen [PSA] ≤20 ng/mL, and Grade Group 1-2) prostate cancer and 619 men with unfavorable-risk (clinical stage cT2cN0M0, PSA of 20-50 ng/mL, or Grade Group 3-5) prostate cancer diagnosed in 2011 through 2012, accrued from 5 Surveillance, Epidemiology and End Results Program sites and a US prostate cancer registry, with surveys through September 2017. EXPOSURES: Treatment with active surveillance (n = 363), nerve-sparing prostatectomy (n = 675), external beam radiation therapy (EBRT; n = 261), or low-dose-rate brachytherapy (n = 87) for men with favorable-risk disease and treatment with prostatectomy (n = 402) or EBRT with androgen deprivation therapy (n = 217) for men with unfavorable-risk disease. MAIN OUTCOMES AND MEASURES: Patient-reported function, based on the 26-item Expanded Prostate Index Composite (range, 0-100), 5 years after treatment. Regression models were adjusted for baseline function and patient and tumor characteristics. Minimum clinically important difference was 10 to 12 for sexual function, 6 to 9 for urinary incontinence, 5 to 7 for urinary irritative symptoms, and 4 to 6 for bowel and hormonal function. RESULTS: A total of 2005 men met inclusion criteria and completed the baseline and at least 1 postbaseline survey (median [interquartile range] age, 64 [59-70] years; 1529 of 1993 participants [77%] were non-Hispanic white). For men with favorable-risk prostate cancer, nerve-sparing prostatectomy was associated with worse urinary incontinence at 5 years (adjusted mean difference, -10.9 [95% CI, -14.2 to -7.6]) and sexual function at 3 years (adjusted mean difference, -15.2 [95% CI, -18.8 to -11.5]) compared with active surveillance. Low-dose-rate brachytherapy was associated with worse urinary irritative (adjusted mean difference, -7.0 [95% CI, -10.1 to -3.9]), sexual (adjusted mean difference, -10.1 [95% CI, -14.6 to -5.7]), and bowel (adjusted mean difference, -5.0 [95% CI, -7.6 to -2.4]) function at 1 year compared with active surveillance. EBRT was associated with urinary, sexual, and bowel function changes not clinically different from active surveillance at any time point through 5 years. For men with unfavorable-risk disease, EBRT with ADT was associated with lower hormonal function at 6 months (adjusted mean difference, -5.3 [95% CI, -8.2 to -2.4]) and bowel function at 1 year (adjusted mean difference, -4.1 [95% CI, -6.3 to -1.9]), but better sexual function at 5 years (adjusted mean difference, 12.5 [95% CI, 6.2-18.7]) and incontinence at each time point through 5 years (adjusted mean difference, 23.2 [95% CI, 17.7-28.7]), than prostatectomy. CONCLUSIONS AND RELEVANCE: In this cohort of men with localized prostate cancer, most functional differences associated with contemporary management options attenuated by 5 years. However, men undergoing prostatectomy reported clinically meaningful worse incontinence through 5 years compared with all other options, and men undergoing prostatectomy for unfavorable-risk disease reported worse sexual function at 5 years compared with men who underwent EBRT with ADT.
引用
- Hoffman KE, Penson DF, Zhao Z, et al. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA. 2020. PMID: 31935027. doi:10.1001/jama.2019.20675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。